(Urothelial Cancer) Is Erdafitinib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- July 31, 2023
- Read time: 2 minutes
From June 2–6, 2023, Yohann Loriot et al. of Gustave Roussy Institute presented at ASCO 2023 in Chicago, USA, the efficacy and safety of Erdafitinib in the THOR Phase 3 clinical trial for FGFR-altered advanced urothelial cancer patients with prior immune checkpoint inhibitor therapy.
The THOR Phase 3 clinical trial randomly assigned FGFR-altered advanced urothelial cancer patients with prior immune checkpoint inhibitor therapy in a 1:1 ratio to the Erdafitinib group (once daily 8 mg, maximum 9 mg, N=136) or the chemotherapy group (N=130). The primary endpoint was overall survival, and secondary endpoints were progression-free survival, objective response rate, and safety.
Patient demographics: Median age was 66 years in the Erdafitinib group and 69 years in the chemotherapy group. Metastatic disease: Erdafitinib group 74.3%, chemotherapy group 74.6%. Low PD-L1 expression: Erdafitinib group 92.7%, chemotherapy group 86.1%. Prior first-line treatment: Erdafitinib group 33.1%, chemotherapy group 25.4%. Prior second-line treatment: Erdafitinib group 66.2%, chemotherapy group 74.6%.
Primary endpoint median overall survival: Erdafitinib group 12.1 months / chemotherapy group 7.8 months — the Erdafitinib group showed significant improvement.
Secondary endpoint median progression-free survival: Erdafitinib group 5.6 months / chemotherapy group 2.7 months — the Erdafitinib group showed significant improvement. Objective response rate: Erdafitinib group 46% / chemotherapy group 12% — the Erdafitinib group was significantly higher.
Regarding safety, the incidence of Grade 3–4 adverse events was: Erdafitinib group 46% / chemotherapy group 46%. Serious adverse event incidence: Erdafitinib group 13% / chemotherapy group 24%. Treatment-related deaths: Erdafitinib group 1 patient / chemotherapy group 6 patients.
Based on the THOR trial results, Yohann Loriot et al. stated: In FGFR-altered advanced urothelial cancer patients with prior immune checkpoint inhibitor therapy, Erdafitinib treatment showed improvement in overall survival, progression-free survival, and objective response rate compared to chemotherapy.
Source: https://meetings.asco.org/abstracts-presentations/226592
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4